Muscarinic Acetylcholine Receptor M4 (CHRM4) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 67

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Pipeline Review, H1 2018

Summary

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by the CHRM4 gene. It mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.

Muscarinic Acetylcholine Receptor M4 (CHRM4) pipeline Target constitutes close to 14 molecules. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 2 and 8 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders, Mouth and Dental Disorders and Ophthalmology which include indications Alzheimer's Disease, Schizophrenia, Psychosis, Amnesia, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Bipolar Disorder (Manic Depression), Chromosomal Disorders, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Parkinson's Disease, Presbyopia, Rett Syndrome, Sialorrhoea, Systolic Hypertension and Tuberous Sclerosis.

The latest report Muscarinic Acetylcholine Receptor M4 (CHRM4) - Pipeline Review, H1 2018, outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M4 (CHRM4)

- The report reviews Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics and enlists all their major and minor projects

- The report assesses Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M4 (CHRM4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M4 (CHRM4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Overview
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Companies Involved in Therapeutics Development
Anavex Life Sciences Corp
AstraZeneca Plc
Heptares Therapeutics Ltd
Karuna Pharmaceuticals Inc
NeuroHealing Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drug Profiles
(aceclidine + tropicamide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(trospium chloride + xanomeline) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANAVEX-273 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANAVEX-273 + donepezil hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-0016878 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSX-0527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSX-0527f - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSX-0559 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSX-0559f - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tropicamide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0467154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-6000918 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Dormant Products
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Discontinued Products
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Product Development Milestones
Featured News & Press Releases
Apr 17, 2018: Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX2-73 in Parkinson's Disease Dementia and Provides Clinical Study Update for ANAVEX2-73 in Rett Syndrome
Mar 07, 2018: Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)
Jan 16, 2018: Anavex Life Sciences Reports Potential Normalization of Hypertension with ANAVEX2-73 Published in The Journal of Clinical Hypertension
Nov 04, 2017: Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer's Disease Treatment ANAVEX2-73 at 2017 Clinical Trials on Alzheimer's Disease Meeting
Oct 30, 2017: Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation's Parkinson's Disease Therapeutics Conference
Oct 27, 2017: Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017
Oct 12, 2017: Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX2-73 in Mild-to-Moderate Alzheimer's disease Patients
Sep 05, 2017: Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX 2-73
Aug 31, 2017: First Subject Dosed in Phase 1 Clinical Study of Novel Selective MUSCARINIC M4 Agonist in Development to Treat Major Symptoms of Alzheimers Disease
Jul 20, 2017: Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board
May 22, 2017: Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome-Data Presented at Antiepileptic Drug Trials XIV 2017 Conference
May 19, 2017: Karuna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical Meetings
Jan 19, 2017: Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017
Dec 15, 2016: Karuna Pharmaceuticals and PureTech Health Announce Positive Results from Tolerability Proof-of-Concept Study of KarXT, Being Developed for Schizophrenia and Alzheimers
Dec 08, 2016: Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer's disease Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Anavex Life Sciences Corp, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Heptares Therapeutics Ltd, H1 2018
Pipeline by Karuna Pharmaceuticals Inc, H1 2018
Pipeline by NeuroHealing Pharmaceuticals Inc, H1 2018
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
  • 2018-2023 Global PEGylated Proteins Consumption Market Report
    Published: 15-Jun-2018        Price: US 4660 Onwards        Pages: 138
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global PEGylated Proteins market for 2018-2023. PEGylating has been widely used as a post-production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins since the first PEGylated product was approved by Food and Drug Administration in the early 1990s. The threat of substitutes arises when there a......
  • 2018 Top 5 PEGylated Proteins Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 15-Jun-2018        Price: US 4960 Onwards        Pages: 125
    PEGylating has been widely used as a post-production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins since the first PEGylated product was approved by Food and Drug Administration in the early 1990s. The threat of substitutes arises when there are similar products developed by competitors which satisfy the market needs. When consumers have access to substitute products which can satisfy their market needs, then manufacturer......
  • 2018-2023 Global Erythropoietin Consumption Market Report
    Published: 15-Jun-2018        Price: US 4660 Onwards        Pages: 131
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Erythropoietin market for 2018-2023. Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adult......
  • 2018 Top 5 Erythropoietin Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 15-Jun-2018        Price: US 4960 Onwards        Pages: 125
    Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood. Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, t......
  • Global Enzymatic Debridement Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Jun-2018        Price: US 3480 Onwards        Pages: 129
    Enzymatic Debridement uses chemical enzymes to assist in wound healing. Enzymes that help slough off the dead tissue are often available as part of a topic ointment; however, the ointment must be carefully applied to only the currently dead tissue - if the enzymes come in contact with healthy tissue, they could cause issues. Scope of the Report: This report focuses on the Enzymatic Debridement in global market, especially in North America, Europe and Asia-Pacific, South Ame......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Enzymatic Debridement Market 2018, Forecast to 2023
    Published: 15-Jun-2018        Price: US 4880 Onwards        Pages: 133
    Enzymatic Debridement uses chemical enzymes to assist in wound healing. Enzymes that help slough off the dead tissue are often available as part of a topic ointment; however, the ointment must be carefully applied to only the currently dead tissue - if the enzymes come in contact with healthy tissue, they could cause issues. Scope of the Report: This report focuses on the Enzymatic Debridement in global market, especially in North America, Europe and Asia-Pacific, South Ame......
  • Global Vaccine Market, People Vaccinated, Administered, Immunization, By Disease, By End User, Companies
    Published: 14-Jun-2018        Price: US 1990 Onwards        Pages: 355
    Global Vaccine Market is projected to reach US$ 70 Billion by the year 2024. The vaccine market is likely to witness a significant growth throughout the forecast period due to the growing prevalence of diseases, increasing government and non-government funding for vaccine development & distribution and increasing investments by companies to develop new vaccines. Furthermore, growing demand for preventive vaccines, rising consciousness about vaccination coupled with mounting demand from th......
  • Global Celery Seed Extract Solid Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 13-Jun-2018        Price: US 3480 Onwards        Pages: 135
    Celery seed solid extract and oil are majorly used for healthcare benefits as anti-spasmodic, nerve stimulant, stimulant and tonic in asthma, rheumatoid arthritis, intestinal antiseptic. The essential oil of celery seed comprise of sesquiterpene alcohols, sedanolide, d-limonene, selinene, and sedanonic anhydride. Celery oil is mostly used for flavoring of food and perfumes. Scope of the Report: This report focuses on the Celery Seed Extract Solid in global market, especial......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Celery Seed Extract Solid Market 2018, Forecast to 2023
    Published: 13-Jun-2018        Price: US 4880 Onwards        Pages: 128
    Celery seed solid extract and oil are majorly used for healthcare benefits as anti-spasmodic, nerve stimulant, stimulant and tonic in asthma, rheumatoid arthritis, intestinal antiseptic. The essential oil of celery seed comprise of sesquiterpene alcohols, sedanolide, d-limonene, selinene, and sedanonic anhydride. Celery oil is mostly used for flavoring of food and perfumes. Scope of the Report: This report focuses on the Celery Seed Extract Solid in global market, especial......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs